Sugammadex Injection, Solution
Product Images NDC 68083-442

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Sugammadex (NDC 68083-442). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Gland Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Sugammadex-spl-fig-1 (Sugammadex Spl Fig 1)

Label for Sugammadex Injection 200 mg/2 mL (100 mg/mL) solution in a 2 mL single-dose vial. The label indicates intravenous use only, storage instructions at 20°C to 25°C, and protection from light. Manufactured by Gland Pharma Limited in Hyderabad, India. Includes NDC 68083-441-01 and a barcode.*

FDA Label Image

Sugammadex-spl-fig-2 (Sugammadex Spl Fig 2)

Packaging label for Sugammadex Injection 200 mg/2 mL (100 mg/mL) solution for intravenous use. The label states it is for prescription use only and includes 10 x 2 mL single-dose vials. Manufactured by Gland Pharma Limited, Hyderabad, India. The label includes storage instructions and a barcode, with the NDC 68083-441-10.*

FDA Label Image

Sugammadex-spl-fig-3 (Sugammadex Spl Fig 3)

Label for Sugammadex Injection 500 mg/5 mL (100 mg/mL) sterile solution in a 5 mL single-dose vial. For intravenous use only. Storage instructions specify 20°C to 25°C and protection from light. Labeler is Gland Pharma Limited, Hyderabad, India, with NDC 68083-442-01.*

FDA Label Image

Sugammadex-spl-fig-4 (Sugammadex Spl Fig 4)

This packaging label is for Sugammadex Injection 500 mg/5 mL (100 mg/mL), an intravenous injection solution supplied by Gland Pharma Limited. The label shows a box containing 10 single-dose vials of 5 mL each. The box is marked with the NDC 68083-442-10 and specifies storage instructions, formulation details, and manufacturer information.*

FDA Label Image

Sugammadex-spl-image-1 (Sugammadex Spl Image 1)

A cumulative recovery rate graph comparing sugammadex and neostigmine recovery times in minutes. The x-axis represents time to recovery (0 to 120 minutes), and the y-axis shows cumulative recovery rate (0 to 1). A legend box provides median recovery times: sugammadex 1.4 minutes (Q1 1.2, Q3 1.7), neostigmine 21.5 minutes (Q1 9.8, Q3 42.0).*

FDA Label Image

Sugammadex-spl-image-2 (Sugammadex Spl Image 2)

A cumulative recovery rate graph comparing sugammadex and neostigmine over time. The x-axis shows time to recovery in minutes (0 to 120), and the y-axis shows cumulative recovery rate from 0 to 1. Sugammadex reaches near-complete recovery much faster than neostigmine, with medians of 2.1 minutes versus 29.0 minutes respectively, as indicated in the inset box.*

FDA Label Image

Sugammadex-spl-structure-1 (Sugammadex Spl Structure 1)

Chemical structure of sugammadex depicted as a complex cyclic molecule with multiple hydroxyl groups and sodium carboxylate substituents. The structure shows stereochemistry and the macrocyclic arrangement characteristic of sugammadex.*

FDA Label Image

Sugammadex-spl-structure-2 (Sugammadex Spl Structure 2)

Chemical structure of sugammadex, depicted as a cyclic molecular structure with multiple sugar-like rings and various functional groups including sodium carboxylates.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.